Bedford, MA (February 2016) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today its selection by the Strategic News Service as a 2016 FiReStarter company to be featured at the 14th annual Future in Review (FiRe) conference. FiRe 2016 will take place September 27-30, 2016, at the Stein Eriksen Lodge Deer Valley in Park City, Utah.
Described by The Economist as “the best technology conference in the world,” FiRe features global thought leaders in technology and the global economy, including Elon Musk, Craig Venter, Michael Dell, Vint Cerf, Leroy Hood, Patti Grace Smith, Mark Hurd, Paul Jacobs, and many others. FiReStarters are selected based on the strength of their potential to bring positive change to the world, and are showcased at the FiRe conference, in panels throughout the event, and with ongoing relationships introduced and supported by SNS.
“We are honored to be able to take part in the FiRe conference and to share our technology for addressing the critical issues of hospital infections and antimicrobial resistance,” said Don Straus, CEO of First Light Biosciences.
“One of the great risks associated with modern healthcare is infection acquired at the point of treatment. We are delighted to have First Light Biosciences as a FiReStarter this year, and look forward to helping them promote a unique solution to this growing problem,” said Mark Anderson, FiRe Chair and CEO of the Strategic News Service.
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightibio.com